secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2026-05-11T23:59:59+00:00
Accession:  0001193125-26-215674
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo Therapeutics Q1 net loss $20.2M; cash $227.6M; LX2006 pivotal trial protocol submitted to FDA
--------------------------------------------------------------------------------

- Net loss $20.2M ($0.25/share) vs $32.7M ($0.99) in Q1 2025; R&D $15.7M, G&A $6.6M.
- Cash, equivalents & investments $227.6M at March 31, 2026; expected runway into 2028.
- LX2006 SUNRISE-FA2 pivotal protocol and SAP submitted to FDA; initiation expected Q2 2026.
- Appointed Laura Sepp-Lorenzino, Ph.D., former CSO of Intellia, to Board of Directors.
- ASGCT presentations: LX2006 shows significant mFARS improvement vs natural history (p=0.003); LX2022 preclinical data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526215674/0001193125-26-215674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526215674/lxeo-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-215674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer